Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent

Cardiovascular Drug Reviews

Volumn 15, Issue 2, 1997, Pages 137-156

  Salata, Joseph J ^b   Brooks, Robert R ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antiarrhythmic drug; Azimilide; NE 10064; Potassium channel

Indexed keywords

ANTIARRHYTHMIC AGENT; AZIMILIDE; POTASSIUM ION; SOTALOL;

ACTION POTENTIAL; BLOOD PRESSURE; DOG; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROCARDIOGRAM; GUINEA PIG; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE WALL; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; ORAL DRUG ADMINISTRATION; POTASSIUM CURRENT; PRIORITY JOURNAL; PURKINJE CELL; QT INTERVAL; REFRACTORY PERIOD; REPOLARIZATION; REVIEW; SUDDEN DEATH;

EID: 0030880632     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1997.tb00328.x     Document Type: Review

References (65)

1. Ks blockade. PACE 1996;19:644.
2. + current in a novel immortalized murine cardiac cell line (HL-1). Pharmacologist 1997;39:57.
3. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 1993;22:810-818.
4. Brandt MA, Maynard AE. NE-10064 exhibits class III antiarrhythmic effects after intravenous or oral administration in conscious dogs. FASEB J 1994;8:A7.
5. Bril A, Dusseau C, Forest M, Cheval B, Faivre J. Comparative effects of BRL-32872 and azimilide on action potential duration in guinea pig isolated papillary muscle. FASEB J 1996;10:A65.
6. Brooks RR, Butterfield JL. The class III antiarrhythmic NE-10064 increases QTc interval with minor hemodynamic effects in anesthetized dogs. Can J Physiol Pharmacol (Suppl 1) 1994;72:79.
7. Brooks RR, Carpenter JF, Jones SM, Gregory CM. Effects of dantrolene sodium in rodent models of cardiac arrhythmia. Eur J Pharmacol 1989;164:521-530.
8. Brooks RR, Carpenter JF, Miller KE, Maynard AE. Efficacy of the class IJJ antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia. Proc Soc Exp Biol Med 1996;212:84-93.
9. sK channels expressed in Xenopus oöcytes by the novel class III antiarrhythmic NE-10064. Eur J Pharmacol 1994;264: 33-37.
10. Ks in guinea pig cardiac myocytes. Biochem Biophys Res Commun 1994;202:265-270.
11. Conder ML, Hess TA, Smith MA, D'Alonzo AJ, McCullough JR. The effects of NE-10064 on cardiac sodium channels. FASEB J 1994;8:A609.
12. + currents in cardiac cells. Biophys J 1994;66:A326.
13. Davies MP, Freeman LC, Kass RS. Dual actions of the novel class III antiarrhythmic drug NE-10064 on delayed potassium channel currents in the guinea pig ventricular and sinoatrial node cells. J Pharmacol Exp Ther 1996;276:1149-1154.
14. Drexler AP, Al-Khalidi H, Maynard AE, et al. Comparison of azimilide dihydrochloride (NE-10064) and selected class TJI antiarrhythmic agents in a rabbit model of proarrhythmia. FASEB J 1996;10:A33.
15. Ks). Biophys J 1995; 68:A111.
16. Drexler AP, Micklas JM, Brooks RR. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. J Cardiovasc Pharmacol 1996;28:848-855.
17. Eigenberger B, Suessbrich H, Salata JJ, Jurkiewicz NK, Lang F, Busch AE. Characterization of the blockade of HERG channel blockade by the class III antiarrhythmic azimilide: Mechanism and specificity. Pflügers Arch-Eur J Physiol 1997;433:R88.
18. Fermini B, Jurkiewicz NK, Jow B, et al. Use-dependent effects of the class IEI antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: Block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995;26:259-271.
19. Gintant GA. Paradoxical effect of combined administration of class III agents on the canine ventricular action potential. Circulaiion 1996;94:I-160.
20. Ks in canine ventricular myocytes: Effects of NE-10064 (azimilide). Circulation 1994;90:I-146.
21. Gintant GA. Two components of delayed rectifier current in canine atrium and ventricle - does I-KS play a role in the reverse rate dependence of class III agents? Circ Res 1996;78:26-37.
22. Groh WJ, Gibson KJ, Maylie JG. Azimilide (NE-10064) prolongs action potential duration in a reverse rate-dependent manner in guinea pig ventricular muscle. PACE 1995;18:853.
23. Groh WJ, Maylie JG. Efficacy of NE-10064 in maintaining repolarizing current block after d,l-sotalol and isoproterenol. PACE 1994;17:755.
24. Harrison DC. Current classification of antiarrhythmic drugs as a guide to their rational clinical use. Drugs 1986;31:93-95.
25. sK inhibition by the novel class III antiarrhythmic azimihde (NE-10064). Eur J Pharmacol 1995;291:205-208.
26. Jackson KN, Lowe ER, Benn DR, Drexler AP, Kostreva DR, Mittelstadt SW. Effect of azimilide on left ventricular function in anesthetized dogs during ischemia. FASEB J 1996;10:A429.
27. + current by dofetilide. Circ Res 1993;72:75-83.
28. Kulbertus HE. Antiarrhythmic treatment of atrial arrhythmias. J Cardiovasc Pharmacol 1991;17:S32-S35.
29. + currents in human atrial and ventricular myocytes. Circulation (Suppl 8) 1995;92:I-575.
30. Lascault G, Asta J, Cameron D, Waxman MB. Electrophysiologic effect of sodium dantrolene on cardiac action potential. Circulation 1982;66:II-294.
31. Lavine SJ, Prcevski P. Comparison of hemodynamic effects of 2 type III antiarrhythmic agents in dogs with chronic ischemic left ventricular dysfunction. J Invest Med 1996;44:211A.
32. Maynard AE, Benn DR, Lowe ER, Kostreva DR, Mittelstadt SW. Beta-adrenergic effects of intravenous azimilide in the pentobarbital-anesthetized rat. FASEB J 1996;10:A427.
33. McIntosh MA, Tanira M, Pacini D, Kane KA. Comparison of the electrophysiological effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischemia. J Cardiovasc Pharmacol 1994;23: 653-657.
34. Miller KE, Carpenter JF, Brooks RR. An in vitro guinea pig heart model providing contractility and electrophysiology data on antiarrhythmic compounds. Pharmacologist 1988;30:A178.
35. Miller KE, Carpenter JF, Brooks RR. Beta-adrenergic effects of the class III antiarrhythmic agent NE-10064 in the isolated perfused guinea pig heart. FASEB J 1993;7:A108.
36. Kr blocker dofetilide. J Am Coll Cardiol 1997 (in press).
37. Ks) on canine atrial flutter. PACE 1994;17:777.
38. Podrid PJ. Safety and toxicity of antiarrhythmic drug therapy: Benefit versus risk. J Cardiovasc Pharmacol (Suppl 6) 1991;17:S65-S73.
39. Poole JE, Bardy GH. Sudden cardiac death. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology from Cell to Bedside. Philadelphia: W.B. Saunders Company, 1995:812-832.
40. Pong SF, Kinney CM, Moorehead TJ. Binding profiles of NE-10064, a novel class III antiarrhythmic agent, to rat brain receptors. FASEB J 1993;7:A474.
41. Qi X, Newman D, Dorian P. Azimilide (NE-10064) increases coherence during ventricular fibrillation in the anesthetized dog. PACE 1996;19:730.
42. Qi X, Newman D, Dorian P. Class III effect of azimilide (NE-10064). Prevention of reverse use-dependence in open-chest dogs. PACE 1996;19:692.
43. Qi X, Newman D, Dorian P. Class III effect of azimilide (NE-10064): Prevention of reverse use-dependence on monophasic action potential duration in open-chest dogs. Circ Res 1997 (in press).
44. Reiser HJ, Sullivan ME. Antiarrhythmic drug therapy: New drugs and changing concepts. Fed Proc 1986; 45:2206-2212.
45. Restivo M, Hegazy M, Caref EB, et al. Termination and prevention of circus movement atrial flutter in the sterile pericarditis model by a novel type III agent, azimilide (NE-10064). Circulation 1994;90:I-413.
46. Restivo M, Hegazy M, El-Hamamy M, et al. Antiarrhythmic efficacy of azimilide dihydrochloride on functional circus movement atrial flutter in the canine right atrial enlargement model. PACE 1996;19:664.
47. Restivo M, Yin H, Caref EB, Levin R, Assadi MA, Brooks RR. Selective effect of class III antiarrhythmic agents on refractoriness determines efficacy in post infarction reentrant ventricular tachyarrhythmias (VT). Circulation 1996;94:I-161.
48. Rosen MR, Strauss HC, Janse MJ. The classification of antiarrhythmic drugs. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology from Cell to Bedside. Phitadelphia:W.B. Saunders Company, 1995:1277-1286.
49. Salata JJ, Jalife J. Effects of dantrolene sodium on the electrophysiological properties of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1982;220:157-166.
50. Saiata JJ, Wasserstrom JA, Jalife J. Dantrolene sodium: Effects on isolated cardiac tissues. J Mol Cell Cardiol 1983;15:233-243.
51. Sanderson J. The SWORD of Damocles. Lancet 1996;348:2-3.
52. Kr potassium channel. Cell 1995;81:299-307.
53. + current is composed of two currents in guinea pig atrial cells. Am J Physiol 1991;260:H393-H399.
54. Ks, the slow component of the cardiac delayed rectifier. Biophys J 1994;66:A209.
55. + channel. Open-channel block by methanesulfonanilides. Circ Res 1996;78:499-503.
56. Tatla DS, David BC, Malloy KJ, Moorehead TJ. In vitro electrophysiology of NE-10064, a novel and highly selective class III antiarrhythmic agent. FASEB J 1993;7:A107.
57. Ks enhances the arrhythmogenic effect of sympathetic stimulation. Circulation 1996;94:I-160.
58. + channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity. J Cardiovasc Pharmacol 1995;26:847-854.
59. Wade-Whittaker F, Sansone DL, Erickson BK. Rate-dependent effects of azimilide (AZ) and dofetilide (DO) on cardiac refractoriness in the ferret. FASEB J 1996;10:A64.
60. Waldo AL, Camm AJ, deRuyter H, et al. Effect of de-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;236:7-12.
61. + channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). Circ Res 1994;75:870-878.
62. Yao J, Tseng G. Azimilide (NTE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: Dependence on blockade of K, Ca, and Na channels. J Cardiovasc Electrophysiol 1997 (in press).
63. Yao J, Tseng G. Effects of azimilide (NE-10064) on cardiac K channels. J Am Coll Cardiol 1995;Special Issue: 176A.
64. Yu C, Pelosi SS, Calcagno MA (inventors); Norwich Eaton Pharmaceuticals (assignee). 4-Oxocyclic ureas useful as antiarrhythmic and antifibrillatory agents. U.S. Pat. 5,462,940, 1995.
65. Zhang ZH, Boutjdir M, Brooks RR, El-Sherif N. Mechanisms of use-independent effect of a novel class III drug, azimilide: Characterization of the effects on repolarization currents in guinea pig and rat ventricular myocytes. Circ Res 1997 (in press).